NovoLog^® in the pump

By offering your patients NovoLog^® (insulin aspart [rDNA origin] injection) in the pump, you’re offering more than just rapid-acting insulin therapy. The pump offers an alternative delivery system for NovoLog^®.

Since receiving initial FDA approval in 2001, NovoLog^® has been the subject of additional clinical trials and provides the following benefits:

Demonstrated safety and efficacy in adult patients with either type 1 or type 2 diabetes
Remains heat-stable in pumps at normal body temperature (up to 98.6°F)
Low incidence of crystal formation in pumps¹
First rapid-acting insulin approved for both subcutaneous and pump use in children with type 1 diabetes over the age of 2

Rates of unexplained hyperglycemia or infusion set occlusion² vs. glulisine

Monthly rate of unexplained hyperglycemia or perceived infusion set occlusion^2†

A 39-week, randomized, controlled, multinational, open-label, 3-way crossover study enrolling 256 adult patients with type 1 diabetes assigned to 1 of 3 treatment groups [glulisine – NovoLog^® – lispro; NovoLog^® – lispro – glulisine; lispro – glulisine – NovoLog^®] and then “crossed over”
(13 weeks per each intervention).

^†Secondary end point. The primary end point of percentages of patients with unexplained hyperglycemia and/or perceived infusion set occlusion was not significantly different between the treatment groups.

Adapted from van Bon et al, 2011.

In patients with type 1 diabetes, NovoLog^® (insulin aspart [rDNA origin] injection) demonstrated a lower monthly rate of unexplained hyperglycemia or infusion set occlusion vs glulisine (P<0.001)²
Comparison between NovoLog^® and insulin lispro was not reported for any end points in the study

NovoLog^® is the first rapid-acting insulin with an extended in-use time in external insulin pump reservoirs

Change NovoLog^®

NovoLog^® has an extended in-use time of up to 6 days in pump reservoirs as compared with only 48 hours for insulin glulisine.^3,4

Indications and Usage

NovoLog^® (insulin aspart [rDNA origin] injection) is an insulin analog indicated to improve glycemic control in adults and children with diabetes mellitus.

Important Safety Information

NovoLog^® is contraindicated during episodes of hypoglycemia and in patients hypersensitive to NovoLog^® or one of its excipients.

NovoLog^® has a more rapid onset and shorter duration of action than regular human insulin. An injection of NovoLog^® should be immediately followed by a meal within 5 to 10 minutes. Because of the short duration of action of NovoLog^®, a longer-acting insulin also should be used in patients with type 1 diabetes and may be needed in patients with type 2 diabetes. When used in an external subcutaneous insulin infusion pump, NovoLog^® should not be mixed with any other insulin or diluent. Hypoglycemia is the most common adverse effect of all insulin therapies, including NovoLog^®. The timing of hypoglycemia usually reflects the time-action profile of the administered insulins.

Any change of insulin dose should be made cautiously and only under medical supervision. Glucose monitoring is recommended for all patients with diabetes and is particularly important for patients using external pump infusion therapy. As with all insulin preparations, the time course of action of NovoLog^® may vary in different individuals or at different times in the same individual and is dependent on many conditions, including injection site, local blood supply, temperature, and level of physical activity.

Needles and NovoLog^® FlexPen^® must not be shared.

NovoLog^® has not been studied in children with type 2 diabetes or in children with type 1 diabetes under the age of two.

Severe, life-threatening generalized allergy, including anaphylactic reaction, may occur with any insulin product, including NovoLog^®. Adverse reactions observed with NovoLog^® include hypoglycemia, allergic reactions, local injection site reactions, lipodystrophy, rash, and pruritus. Insulin, particularly when given intravenously or in settings of poor glycemic control, may cause hypokalemia. Like all insulins, NovoLog^® requirements may be reduced in patients with renal impairment or hepatic impairment.

Insulin lispro is not approved for use in children by subcutaneous continuous infusion via external insulin pump.

An injection of NovoLog^® should be immediately followed by a meal within 5 to 10 minutes.

All pregnancies have a background risk of birth defects, loss, or other adverse outcome regardless of drug exposure, This background risk is increased in pregnancies complicated by hyperglycemia and may be decreased with good metabolic control. It is essential for patients with diabetes or history of gestational diabetes to maintain good metabolic control before conception and throughout pregnancy.

Please click here for Prescribing Information.

References

Bode BW, Strange P. Efficacy, safety, and pump compatibility of insulin aspart used in continuous subcutaneous insulin infusion therapy in patients with type 1 diabetes. Diabetes Care. 2001;24(1):69-72.
van Bon AC, Bode BW, Sert-Langeron C, DeVries JH, Charpentier G. Insulin glulisine compared to insulin aspart and to insulin lispro administered by continuous subcutaneous insulin infusion in patients with type 1 diabetes: a randomized controlled trial. Diabetes Technol Ther. 2011;13(6):607-614.
Apidra^® [package insert]. Bridgewater, NJ: sanofi-aventis US LLC, 2009.
NovoLog^® [prescribing information]. Princeton, NJ: Novo Nordisk Inc; 2011.

NovoLog® in the pump

Rates of unexplained hyperglycemia or infusion set occlusion2 vs. glulisine

Monthly rate of unexplained hyperglycemia or perceived infusion set occlusion2†

NovoLog® is the first rapid-acting insulin with an extended in-use time in external insulin pump reservoirs

Change NovoLog®